Committee Hears Bill to Ban Prior Authorization for FDA-Approved HIV Antivirals
The House Healthcare and Wellness Committee heard Substitute Senate Bill 6,183, which would require health plans—including those for public and school employees—to cover FDA-approved HIV antiviral drugs without prior authorization, step therapy, or other utilization management beginning Jan. 1, 2027; the prime sponsor framed it as part of efforts to end HIV in Washington.
The full story
The House Healthcare and Wellness Committee convened a public hearing on Substitute Senate Bill 6,183, which would prohibit health plans issued or renewed on or after Jan. 1, 2027, from imposing prior authorization, step-therapy or other utilization-management protocols on FDA-approved antiviral drugs used to treat or prevent HIV.
Sign up to keep reading.
Your free newsletter brings you what your city council, county, and school board discussed and decided.
Keep reading for free
Create a free account to finish this story and see the video, transcript and key details.
Continue with GoogleContinue with emailAlready have an account? Log in